4-溴-3-(三氟甲基)苯磺酰基氯 | 351003-47-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-溴-3-(三氟甲基)苯磺酰基氯
• 中文别名: 4-溴-3-三氟甲基-苯磺酰氯；4-溴-3-三氟甲基苯磺酰氯；4-溴-3-(三氟甲基)苯磺酰氯
• 英文名称: 4-bromo-3-(trifluoromethyl)benzenesulphonyl chloride
• 英文别名: 3-trifluoromethyl-4-bromobenzenesulfonyl chloride；4-bromo-3-trifluoromethylbenzenesulfonyl chloride；4-bromo-3-trifluoromethyl-benzene-1-sulfonyl chloride；4-bromo-3-(trifluoromethyl)phenyl-1-sulfonyl chloride；4-Bromo-3-(trifluoromethyl)benzenesulfonyl chloride
• CAS: 351003-47-9
• 化学式: C₇H₃BrClF₃O₂S
• mdl: MFCD03094391
• 分子量: 323.518
• InChiKey: QCFIMBHKZZLZAE-UHFFFAOYSA-N

物化性质

• 熔点：
  32-33°C
• 沸点：
  92-94°C/0.35mm
• 密度：
  1.833 g/mL at 25 °C(lit.)
• 闪点：
  >230 °F
• 稳定性/保质期：

  避免与还原剂、碱、活性金属、水、高温、火焰和潮湿接触。

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险等级：
  8
• 危险品标志：
  C
• 危险类别码：
  R34
• 危险品运输编号：
  UN 3265 8/PG 2
• WGK Germany：
  3
• 海关编码：
  2904909090
• 包装等级：
  III
• 危险类别：
  8
• 安全说明：
  S26,S36/37/39,S45
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H314
• 储存条件：
  保存方法：密闭、阴凉、通风干燥处。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-Bromo-3-(trifluoromethyl)benzenesulfonyl chloride
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H314: Causes severe skin burns and eye damage
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P310: Immediately call a POISON CENTER or doctor/physician

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-3-(trifluoromethyl)benzenesulfonyl chloride
CAS number: 351003-47-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
This product should be handled only by, or under the close supervision of, those properly qualified
Handling:
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H3BrClF3O2S
Molecular weight: 323.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen fluoride, hydrogen bromide,
sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN3265 Class: 8 Packing group: II
Proper shipping name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S. (4-Bromo-3-(trifluoromethyl)benzenesulfonyl
chloride)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴-3-(三氟甲基)苯磺酰基氯 在 四(三苯基膦)钯 potassium carbonate 、 三乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 88.0h， 生成 7-{[4-methyl-3-(trifluoromethyl)phenyl]sulfonyl}-2,7-diazaspiro[4.5]decan-1-one
  参考文献：
  名称：

  [EN] SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS
  [FR] DÉRIVÉS SPIROCYCLIQUES PRÉSENTANT UNE AFFINITÉ POUR LES CANAUX CALCIQUES

  摘要：

  这项发明涉及具有亲和力的新颖螺环衍生物 Cav2.2 钙通道，并且能够干扰 Cav2.2 钙通道；其制备方法；含有它们的药物组合物；以及在治疗疼痛方面使用这类化合物。

  公开号：

  WO2011141728A1

文献信息

• NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS
  申请人：Stewart Andrew O.

  公开号：US20100130558A1

  公开（公告）日：2010-05-27

  The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein L 1 , L 2 , R 1 , R 2 , and R 3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本申请涉及含有式（I）化合物的钙通道抑制剂，其中L1、L2、R1、R2和R3如规范中所定义。本申请还涉及包含这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。
• [EN] THIAZOLES AS MODULATORS OF RORyt<br/>[FR] THIAZOLES UTILISÉS COMME MODULATEURS DE RORYT
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2016069976A1

  公开（公告）日：2016-05-06

  The present invention comprises compounds of Formula I. Formula I wherein: R1, R2, R3, R4, R5, R7, R8, and (A) are defined in the specification. The invention also comprises a compound of Formula I for use in a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a compound for use in a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明包括公式I的化合物。公式I中：R1、R2、R3、R4、R5、R7、R8和(A)在说明书中定义。该发明还包括用于治疗或改善综合症、紊乱或疾病的公式I化合物，其中所述综合症、紊乱或疾病为类风湿性关节炎或银屑病。该发明还包括用于通过管理治疗有效量的至少一个权利要求1的化合物来调节哺乳动物中RORγt活性的化合物。
• BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS
  申请人：Xenon Pharmaceuticals Inc.

  公开号：US20180162868A1

  公开（公告）日：2018-06-14

  This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

  这项发明涉及苯磺酰胺化合物，作为其立体异构体、对映异构体、互变异构体或它们的混合物；或其药学上可接受的盐、溶剂合物或前药，用于治疗与电压门控钠通道相关的疾病或症状，如癫痫和/或癫痫发作障碍。
• The synthesis and antistaphylococcal activity of N-sulfonaminoethyloxime derivatives of dehydroabietic acid
  作者：Wen-Ming Zhang、Yang Yao、Teng Yang、Xue-Ying Wang、Zhen-Yun Zhu、Wen-Tao Xu、Hai-Xia Lin、Zhao-Bing Gao、Hu Zhou、Cai-Guang Yang、Yong-Mei Cui

  DOI：10.1016/j.bmcl.2018.03.062

  日期：2018.6

  investigated for their antibacterial activity against Staphylococcus aureus Newman strain and multidrug-resistant strains (NRS-1, NRS-70, NRS-100, NRS-108 and NRS-271). Most of the target compounds having chloro, bromo, trifluoromethyl phenyl moiety exhibited potent in vitro antistaphylococcal activity. The meta-CF3 phenyl derivative T23 showed the highest activity with MIC of 0.39–0.78 μg/mL against

  合成了一系列脱氢松香酸的N-磺氨基乙基肟衍生物，并研究了它们对金黄色葡萄球菌Newman菌株和耐多药菌株（NRS-1，NRS-70，NRS-100，NRS-108和NRS-271）的抗菌活性。具有氯，溴，三氟甲基苯基部分的大多数目标化合物均显示出有效的体外抗葡萄球菌活性。所述元-CF 3苯基衍生物T23表现出与打击0.39-0.78微克/毫升的MIC最高活性的金黄色葡萄球菌纽曼，而几个类似物显示出相似的强抗菌活性与MIC值0.78和1.56微克/毫升之间对五种多药耐药金黄色葡萄球菌。还评估了T35在SD大鼠血浆中的稳定性和细胞毒性。
• SULFONAMIDE COMPOUNDS AND THE USE
  申请人：OGAWA Masami

  公开号：US20100022601A1

  公开（公告）日：2010-01-28

  The sulfoneamide compounds having the following Formula (1), which can be used as an effective component of a CaSR antagonizing agent useful for prophylaxis and/or treatment of bone disorders including osteoporosis and etc., are provided. The compounds have an excellent activity of promoting PTH secretion. In addition, the compounds are useful as an effective component of a medicament for the prophylaxis and/or treatment of bone disorders such as osteoporosis, bone fracture, hypoparathyroidism and the like.

  提供以下式(1)的磺酰胺化合物，可用作预防或治疗包括骨质疏松症等骨疾病的CaSR拮抗剂的有效成分。这些化合物具有促进PTH分泌的卓越活性。此外，这些化合物还用作预防或治疗骨质疏松症、骨折、低甲状旁腺功能等骨疾病药物的有效成分。